Full Text
Cost Utility of Sequential Adjuvant Trastuzumab for HER2/Neu-Positive Breast Cancer

Abstract

Authors

Shelby D. Reed Kevin A. Schulman

Back to Volume 12, Issue 5
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×